Watching The Review Clock: Are US FDA Goal Date Extensions Reason For Optimism?
Executive Summary
Novel agents that received three-month user fee goal date extensions have a slightly higher approval rate than novel applications overall.
You may also be interested in...
Aducanumab Approval Decision Delayed: What’s In The Major Amendment?
From EMBARK data to labeling materials, the potential reasons for the three-month user fee delay are as varied as the ups and downs of the Biogen/Eisai Alzheimer’s candidate’s development saga.
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: